M3554 in advanced solid tumors incl. soft-tissue sarcomas

  Trial name: Anti-GD2 ADC M3554 in Advanced Solid Tumors Agents: M3554 Phase I Status Recruiting Sponsor EMD Serono Research & Development Institute, Inc.   This Phase I trial is testing the safety, dosage, and effectiveness of a new targeted therapy, M3554, for people with advanced cancers incl. soft tissue sarcomas. Further information can be…

Read More

EMERGE 101: Lurbinectedin in Ewing Sarcoma (kids & young adults)

  Trial name: EMERGE 101: Lurbinectedin in Ewing’s Sarcoma Agents: Lurbinectedin Phase I/II Status Recruiting Sponsor Jazz Pharmaceuticals   This phase I/II study evaluates the safety, efficacy, and optimal dosing of lurbinectedin in pediatric and young adult patients with previously treated recurrent or refractory Ewing sarcoma. Further information can be found on clinicaltrials.gov.   WHO…

Read More

DS-2243a in advanced solid tumors incl. synovial sarcoma or myxoid/round cell liposarcoma

First-in-human trial of DS-2243a in participants with advanced solid tumors Agents: DS-2243a Phase I Status Open, recruiting Sponsor Daiichi Sankyo   Further information: https://clinicaltrials.gov/study/NCT06644755   This study evaluates safety, tolerability, and efficacy of DS-2243a as a treatment for participants with advanced solid tumors incl. synovial sarcoma and myxoid/round cell liposarcoma.   WHO is the trial…

Read More

Global Insights on Sarcoma Diagnosis: Preliminary Findings from SPAGN’s Survey

The Sarcoma Patients Advocacy Global Network (SPAGN) is shedding light on the complex and often lengthy journey to a correct sarcoma diagnosis through its Global Survey on Sarcoma Diagnosis Pathways. This initiative aims to capture real-world patient experiences worldwide. At CTOS 2024, preliminary data from over 880 respondents across 40 countries revealed critical insights. Key…

Read More

TANGENT: Emactuzumab in Tenosynovial Giant Cell Tumors

Treatment of Emactuzumab in Tenosynovial Giant Cell Tumors (TANGENT) Agents: Emactuzumab Phase III Status Active, but not recruiting Sponsor SynOx Therapeutics   For further information please also consult ClinicalTrials.gov.   This is a multicenter, phase 3, randomised, double-blind, placebo-controlled study, which aims to evaluate the efficacy and safety of emactuzumab for the treatment of patients…

Read More

INBRX-109 in Ewing Sarcoma & SDH-deficient GIST

  Trial name: INBRX-109 in Ewing sarcomas and SDH-deficient GIST Agents: INBRX-109 in combination with different therapies Phase I Status Recruiting Sponsor Inhibrx, Inc. This is a first-in-human, open-label, non-randomized phase 1 trial of INBRX-109 for patients with locally advanced or metastatic solid tumors including certain subtypes of sarcomas and GIST. Further information can be…

Read More

Tools Anyone Can Use: Become a Social Media Superhero

Creating impactful social media content is essential for patient advocacy groups, but it can often feel like a time-consuming challenge. SPAGN, in collaboration with New Horizons GIST, is hosting a special webinar to empower advocates with tools that simplify and enhance the content creation process. đź“… When: December 6th, 2024 đź•• Time: 6 PM CET…

Read More

UK: Desmoid Fibromatosis UK Patients & Caregivers

UK: Desmoid Fibromatosis UK Patients & Caregivers   Back to members Organisation Profile Desmoid Fibromatosis Patients & Carers U.K ( DFPCUK ) is here to empower, support and educate patients through and beyond their diagnosis of a desmoid tumour. We currently have our facebook page to share information and up to date news on what’s…

Read More

UK: Sarcoma UK

UK: Sarcoma UK Back to members Organisation Profile Sarcoma UK is a national charity that funds vital research, offers support for anyone affected by sarcoma cancer and campaigns for better treatments. It is the only cancer charity in the UK focusing on all types of sarcoma. Our vision Where everyone affected by sarcoma cancer has…

Read More